Ontogeny-based genetic classification defines clinically distinct de novo AML subgroups. (A) Within clinically defined de novo AML, genetic classification identifies subgroups with distinct characteristics, including number of recurrent driver mutations per case, number of cytogenetic abnormalities per case, and age. Box plots are described in Figure 3. (B) Proportion of patients achieving CR after intensive induction chemotherapy based on genetic subtype among older de novo AML patients (left) and clinically defined s-AML patients (right). (C) Event-free survival in clinically defined de novo AML patients age ≥60 years according to genetic ontogeny group. Curves show patients with de novo/pan-AML (red), secondary-type (blue), and TP53 (green) mutations.